aldo-keto reductase family 1 member B10 pseudogene 2Genealiases: []
Q-omics provides the consensus-scored AKR1B10P2 profile across patient tissues and cancer cell-line models. AKR1B10P2 expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, AKR1B10P2 is differentially expressed in 1, with the highest sampling consensus in LUSC. Additionally, AKR1B10P2 RNA expression shows 6,499 significant gene co-expression associations, with the highest sampling consensus in COAD. Together, these results highlight ACC, LUSC, and COAD as cancer lineages where AKR1B10P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for AKR1B10P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes AKR1B10P2 survival associations across molecular data types. AKR1B10P2 RNA expression shows survival associations in the most cancer types (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible AKR1B10P2 RNA expression–survival associations across cancer types. High AKR1B10P2 expression shows unfavorable associations in ACC, SKCM, PCPG, UVM, ESCA and UCEC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for AKR1B10P2 RNA expression.
This table summarizes AKR1B10P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for AKR1B10P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. AKR1B10P2 shows higher tumor expression in LUSC. The LUSC box plot shows higher AKR1B10P2 RNA expression in tumor versus normal tissue (log2 FC = +0.017, t-test p = .049).
This table shows molecular features associated with AKR1B10P2 in patient tissues and cancer cell lines. In patient samples, AKR1B10P2 shows the broadest associations at the RNA and protein expression levels, with COAD recurring as the lineage with the largest associated feature set.
